NASDAQ:TROV Cardiff Oncology Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $11.14 -0.46 (-3.97 %) (As of 01/20/2021 12:00 AM ET) Add Compare Share Today's Range$10.21Now: $11.14▼$11.9250-Day Range$1.19MA: $16.75▼$24.7152-Week Range$0.70Now: $11.14▼$3.46Volume7.10 million shsAverage Volume648,892 shsMarket Capitalization$122.66 millionP/E RatioN/ADividend YieldN/ABeta1.04 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.Read More MarketRank™Overall MarketRank™0.58 out of 5 starsMedical Sector1337th out of 1,928 stocksBiological Products, Except Diagnostic Industry153rd out of 177 stocksAnalyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 - 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Cardiff Oncology. Previous Next 2.9 Community Rank Outperform VotesCardiff Oncology has received 402 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCardiff Oncology has received 296 “underperform” votes. (Add your “underperform” vote.)Community SentimentCardiff Oncology has received 57.59% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cardiff Oncology and other stocks. Vote “Outperform” if you believe TROV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TROV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCardiff Oncology does not currently pay a dividend.Dividend GrowthCardiff Oncology does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cardiff Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.60% of the stock of Cardiff Oncology is held by insiders.Percentage Held by InstitutionsOnly 9.99% of the stock of Cardiff Oncology is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Cardiff Oncology is -3.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cardiff Oncology is -3.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCardiff Oncology has a P/B Ratio of 11.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TROV Previous Symbol CUSIPN/A CIK1213037 Webwww.trovagene.com Phone(858) 952-7570EmployeesN/A Debt Debt-to-Equity Ratio0.12 Current Ratio2.37 Quick Ratio2.37Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$250,000.00 Price / Sales490.65 Cash FlowN/A Price / Cash FlowN/A Book Value$0.94 per share Price / Book11.85Profitability EPS (Most Recent Fiscal Year)($2.80) Net Income$-16,410,000.00 Net Margins-3,688.31% Return on Equity-202.00% Return on Assets-122.92%Miscellaneous Outstanding Shares11,011,000Market Cap$122.66 million Next Earnings DateN/A OptionableOptionable Receive TROV News and Ratings via Email Sign-up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter. Cardiff Oncology (NASDAQ:TROV) Frequently Asked Questions Is Cardiff Oncology a buy right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cardiff Oncology in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cardiff Oncology stock. View analyst ratings for Cardiff Oncology or view MarketBeat's top 5 stock picks. What stocks does MarketBeat like better than Cardiff Oncology? Wall Street analysts have given Cardiff Oncology a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cardiff Oncology wasn't one of them. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. What is Doug Parker's approval rating as Cardiff Oncology's CEO? 1,428 employees have rated Cardiff Oncology CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among Cardiff Oncology's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. How were Cardiff Oncology's earnings last quarter? Cardiff Oncology, Inc. (NASDAQ:TROV) posted its quarterly earnings results on Thursday, February, 27th. The medical research company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.65) by $0.14. The medical research company earned $0.09 million during the quarter. Cardiff Oncology had a negative net margin of 3,688.31% and a negative return on equity of 202.00%. View Cardiff Oncology's earnings history. When did Cardiff Oncology's stock split? How did Cardiff Oncology's stock split work? Shares of Cardiff Oncology reverse split on Wednesday, February 20th 2019. The 1-6 reverse split was announced on Tuesday, February 19th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 19th 2019. An investor that had 100 shares of Cardiff Oncology stock prior to the reverse split would have 17 shares after the split. Who are some of Cardiff Oncology's key competitors? Some companies that are related to Cardiff Oncology include Oyster Point Pharma (OYST), Freeline Therapeutics (FRLN), Autolus Therapeutics (AUTL), Jounce Therapeutics (JNCE), Lineage Cell Therapeutics (LCTX), Proteon Therapeutics (PRTO), CASI Pharmaceuticals (CASI), Cardiff Oncology (CRDF), Aptose Biosciences (APTO), Innate Pharma (IPHA), Innate Pharma (IPHYF), Solid Biosciences (SLDB), Ocugen (OCGN), Eiger BioPharmaceuticals (EIGR) and Cellular Biomedicine Group (CBMG). View all of TROV's competitors. What other stocks do shareholders of Cardiff Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiff Oncology investors own include XOMA (XOMA), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), NVIDIA (NVDA), OPKO Health (OPK), Alnylam Pharmaceuticals (ALNY), Alibaba Group (BABA), Zynerba Pharmaceuticals (ZYNE), Amarin (AMRN) and Idera Pharmaceuticals (IDRA). Who are Cardiff Oncology's key executives? Cardiff Oncology's management team includes the following people: Mark Erlander, Chief Executive Officer & DirectorVicki Kelemen, Chief Operating Officer & Executive Vice PresidentBrigitte Lindsay, Secretary & Vice President-Finance What is Cardiff Oncology's stock symbol? Cardiff Oncology trades on the NASDAQ under the ticker symbol "TROV." What is Cardiff Oncology's stock price today? One share of TROV stock can currently be purchased for approximately $11.14. How big of a company is Cardiff Oncology? Cardiff Oncology has a market capitalization of $122.66 million and generates $250,000.00 in revenue each year. The medical research company earns $-16,410,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis. What is Cardiff Oncology's official website? The official website for Cardiff Oncology is www.trovagene.com. How can I contact Cardiff Oncology? Cardiff Oncology's mailing address is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. The medical research company can be reached via phone at (858) 952-7570 or via email at [email protected] This page was last updated on 1/21/2021 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here
